• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

    2.150 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 16,558
    Open 2.150
    Bid (Size) 2.210 (22)
    Ask (Size) 2.240 (15)
    Prev. Close 2.150
    Today's Range 2.150 - 2.150
    52wk Range 1.085 - 7.140
    Shares Outstanding 48,797,226
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Intraday Session
     
    Via Benzinga

    Performance

    YTD
    -41.3%
    -41.3%
    1 Month
    -14.3%
    -14.3%
    3 Month
    +41.4%
    +41.4%
    6 Month
    +41.4%
    +41.4%
    1 Year
    -61.3%
    -61.3%

    More News

    Read More
    Forecasting The Future: 4 Analyst Projections For C4 Therapeutics
    Via Benzinga
    C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    Why C4 Therapeutics Stock Crushed the Market on Monday
    Via The Motley Fool
    Here are the top movers in Monday's session.
    Via Chartmill
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Which stocks are moving on Monday?
    Via Chartmill
    C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    CCCC Revenue Drops 46%
    Via The Motley Fool
    C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    Which stocks are moving before the opening bell on Thursday?
    Via Chartmill
    C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    C4 Therapeutics to Participate in Upcoming March Investor Conferences
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    AT&T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
    From C4 Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is C4 Therapeutics, Inc. - Common Stock publicly traded?
    Yes, C4 Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does C4 Therapeutics, Inc. - Common Stock trade on?
    C4 Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for C4 Therapeutics, Inc. - Common Stock?
    The ticker symbol for C4 Therapeutics, Inc. - Common Stock is CCCC on the Nasdaq Stock Market
    What is the current price of C4 Therapeutics, Inc. - Common Stock?
    The current price of C4 Therapeutics, Inc. - Common Stock is 2.150
    When was C4 Therapeutics, Inc. - Common Stock last traded?
    The last trade of C4 Therapeutics, Inc. - Common Stock was at 10/01/25 04:00 PM ET
    What is the market capitalization of C4 Therapeutics, Inc. - Common Stock?
    The market capitalization of C4 Therapeutics, Inc. - Common Stock is 104.91M
    How many shares of C4 Therapeutics, Inc. - Common Stock are outstanding?
    C4 Therapeutics, Inc. - Common Stock has 105M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.